Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

agenT 842

Next Previous
Drug Profile

agenT 842

Alternative Names: agenT-842; NY-ESO-1-specific TCR therapy - MiNK Therapeutics; NY-ESO-1:HLA-A*02:01

Latest Information Update: 03 May 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AgenTus Therapeutics
  • Developer MiNK Therapeutics
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cancer

Most Recent Events

  • 03 May 2023 Phase-I/II clinical trials in Cancer in USA (Parenteral) prior to May 2023 (MiNK Therapeutics pipeline, May 2023)
  • 21 Mar 2022 MiNK Therapeutics has patents pending for a TCR for cell therapy targeting NY-ESO-1, prior to March 2022
  • 16 Oct 2019 Pharmacodynamics data from a preclinical trial in Cancer presented at the 5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR- 2019)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top